synteract

LABIOTECH.eu

Unraveling the Complexity of Pediatric Drug Development

50%
Medications given to children, not tested in children

3.8K+
Number of pediatric trials globally

Why Should Drugs Given to Children, Be Tested in Children?

- Different physiology
- Different metabolism
- Variations amongst age groups

Challenges in Pediatric Drug Development

Often rare diseases

Limited number of eligible trial subjects

Complex logistics, rules & regulations

High development costs

Low return of investment

Parents fear their child's participation

Overcoming the Challenges

New regulations & ethical guidance

Educating children, caregivers & parents

Working with advocacy groups

Involvement of experts like CROs

Advantages of Collaborating with CROs Specialized in Pediatrics

- Tailored pediatric development planning
- Access to pediatric networks
- Expertise in regulatory, operations & logistics concerning children & families
- Access to advanced technologies
- Support from preclinical through clinical development, including drug formulation

Synteract's Expertise in Pediatric Drug Development

260+
Pediatric Clinical Trials

25+
Indications

24K+
Patients

Want to learn more about pediatric drug development?
Find out more at **www.synteract.com/Therapeutic-Expertise/Pediatrics**

Sources

Labiotech.eu
Synteract Pediatrics
Synteract
Pharma intelligence

Want to work with us?
Reach out to contact@labiotech.eu

Text: Larissa Warneck
Design and images: Elena Resko

Created with love at labiotech.eu